GLP-1 Prior Authorization: How to Make It Through First Time

The prescriber's office sends the prior authorization. The patient waits. Three days later, the pharmacy calls: denied. The patient calls the prescriber's office. The office checks the denial reason — usually one of a small set — and either resubmits with the missing documentation or asks the patient to schedule a follow-up to gather what was missing the first time.

This sequence is so common that experienced obesity medicine clinicians treat it as the default rather than the exception. Industry surveys and published audits of pharmacy benefit data have repeatedly found first-pass approval rates for obesity medications well below 50%, with most denials reversed on appeal or resubmission. The denial is rarely a final answer. It is usually a documentation gap, which means the second submission, prepared with the gap addressed, tends to succeed.

The patients who get approved on the first attempt tend to share specific documentation patterns. The ones who don't tend to discover, on the denial letter, that one or two items were missing or under-documented. Those items are predictable.

Know which criteria your insurer applies

Before the prescriber submits anything, the patient or office should pull the specific prior authorization criteria for the requested drug from the insurer's PA criteria document. Most major insurers publish these documents on their provider portals, and many make them available to members through the patient portal as well.

The criteria document is the operating manual for the PA request. It typically specifies the required BMI threshold, the qualifying comorbidities, the prior-trial requirements (step therapy), the documentation format the insurer expects, and the duration of the initial approval. Working from the actual criteria document — rather than from general guidance about what insurers usually want — is the single biggest factor in first-pass approval rates.

If the criteria require six months of documented diet-and-exercise attempts, the PA should explicitly cite six months. If they require a trial of phentermine before GLP-1 approval, the chart needs to show the phentermine trial. The PA reviewer is matching the submission against the criteria document line by line, and submissions that mirror the criteria document tend to clear automated review.

Document BMI with specifics, not approximations

BMI documentation is the most common failure point. A note that says "patient has obesity" without a specific BMI measurement and date is insufficient for most automated PA reviews. The submission should include the BMI value calculated to one decimal place, the date of the measurement, and the height and weight used in the calculation.

For patients near the BMI ≥27 threshold (the cutoff requiring a comorbidity), measurement precision matters more. A BMI of 27.0 documented today supports the PA; a BMI of 26.8 documented six months ago does not, even if the patient's current weight would qualify. Patients who are near the threshold benefit from a recent weighing at the prescriber's office before PA submission.

The weight history that helps

Beyond the current BMI, a weight history showing chronicity of obesity strengthens the submission. Several years of consistent weight data, ideally from prior medical records, support the chronic disease framing that justifies pharmacotherapy. This is particularly important for patients applying under the BMI ≥27 + comorbidity criterion, where the weight trajectory contextualises the request.

Document the comorbidity properly

If the PA depends on a qualifying comorbidity, that condition needs to be documented in the chart with an ICD-10 code, a recent encounter note that addresses the condition, and ideally relevant lab or diagnostic data. A note from three years ago mentioning hypertension is weaker than a recent visit note that includes blood pressure measurements, the current management plan, and the active ICD-10 code.

The most commonly successful comorbidities for GLP-1 PA submissions are type 2 diabetes (with hemoglobin A1c documented), prediabetes (with A1c 5.7–6.4%), hypertension (with current blood pressure readings and treatment), dyslipidemia (with lipid panel results), obstructive sleep apnea (with sleep study documentation), cardiovascular disease (with cardiology notes or imaging), non-alcoholic fatty liver disease (with imaging or liver function tests), and osteoarthritis (with imaging or specialist notes).

Donna Ryan at Pennington Biomedical Research Center has written extensively on documentation practices in obesity medicine and notes that comorbidities supported by objective data (labs, imaging, sleep studies) are reviewed more favourably than comorbidities supported only by patient report.

Address step therapy before submission

The chart should document prior weight-loss attempts in specific terms: which interventions were tried, for how long, with what outcome. Vague references to "patient has tried multiple diets" are weaker than specific entries describing a structured programme, its duration, and the weight outcome.

If the insurer requires prior pharmacotherapy trials, the chart needs to show the medication tried, the dose, the duration, and the reason for discontinuation (insufficient efficacy, adverse effects, contraindication, or other). If older agents like phentermine or orlistat were never tried, the prescriber can either initiate a trial before submitting the GLP-1 PA or document a clinical contraindication to those agents and request an exception.

The "have you tried lifestyle modification?" question is essentially never answered by "no" in successful PAs. The clinical record should reflect counselling on diet and exercise, ideally with a documented programme attempt of three to six months, before pharmacotherapy is requested. For many patients, this documentation already exists across past primary care visits and only needs to be assembled.

Choose the right drug for the indication

The four major GLP-1 medications have distinct approved indications, and PA approval tracks those indications closely. Wegovy and Zepbound are approved for chronic weight management. Ozempic and Mounjaro are approved for type 2 diabetes. Requests for Ozempic or Mounjaro for weight loss without a diabetes indication are rarely approved.

For patients with both diabetes and obesity, prescribers sometimes have a choice between the diabetes-indicated product and the obesity-indicated product. The clinical pick depends on the patient's primary indication and the formulary's preferred-product designation. Submitting for the formulary's preferred product when clinically appropriate increases first-pass approval rates.

Detailed coverage of which drug matches which indication, and the broader procedural workflow, is in our companion guide to getting GLP-1 covered by insurance.

Write the clinical rationale to do work

The free-text clinical rationale field on the PA form is where the prescriber explains why this medication, for this patient, now. Short, specific rationale tends to outperform long generic statements.

An effective rationale typically includes:

The patient's specific BMI and qualifying comorbidity, named explicitly. A brief weight history showing chronicity. A summary of prior weight-loss interventions and outcomes. Why the requested medication is clinically appropriate, including reference to relevant guideline support (AGA 2022, AACE 2016, or AHA scientific statements). Any contraindications or intolerances to alternative therapies.

For high-stakes cases (recent cardiovascular event, severe obstructive sleep apnea, advanced metabolic disease), referencing the specific clinical trial evidence supporting use in that population strengthens the submission. The SELECT trial, for example, supports semaglutide use in patients with established cardiovascular disease — a citation that can move an external appeal.

If denied, read the letter carefully

The denial letter must specify the denial reason. The reason determines the path forward.

Documentation deficiency: missing BMI, insufficient comorbidity records, missing prior-attempt history. Fix: prescriber resubmits with the missing data. Usually approved on the second submission.

Step therapy not met: patient hasn't tried a required prior medication or programme. Fix: document the prior trial (if it exists in older records), initiate the trial, or appeal on clinical-grounds (the alternative is contraindicated, has failed previously, or is inappropriate).

Indication mismatch: drug not approved for the patient's condition. Fix: switch to the appropriate drug or document the diabetes indication if applicable.

Coverage exclusion: plan doesn't cover GLP-1s for the requested indication. Fix: this cannot be appealed clinically. Options are HR-mediated benefits review (for employer plans), changing plans during open enrolment, or pursuing cash and manufacturer programmes.

The peer-to-peer review

For complex denials, requesting a peer-to-peer review — a phone call between the prescriber and the insurer's medical director — can resolve ambiguous cases that automated review denied. Peer-to-peer reviews are often available within 5–10 business days of request and produce approvals in a substantial fraction of cases that automated systems denied. The prescribing office initiates this; the patient cannot.

If the internal appeal fails, go external

Under the Affordable Care Act, most commercial plans must offer two appeal levels: an internal appeal handled by the insurer, and an external appeal handled by an independent review organisation (IRO). The IRO's decision is binding on the insurer. External appeals of GLP-1 denials based on medical necessity have higher overturn rates than internal appeals, particularly when the clinical justification extends beyond BMI alone — cardiovascular indication, sleep apnea documented by sleep study, or advanced metabolic disease.

External appeals take 30–60 days. The patient typically initiates the external appeal after exhausting internal options. The insurer must provide instructions for both appeal types in the denial letter.

The reauthorization to plan for

An approved PA typically covers 6–12 months. Many plans require documented weight loss (often 5% at 6 months) to continue authorization. The reauthorization is generally easier than the initial PA — the prescriber documents the response to treatment, confirms continued tolerance, and resubmits. The risk is administrative: a gap in coverage during the reauthorization window can interrupt treatment, with the regain biology that we cover in our piece on maintenance-phase research.

Calendar reminders set at the 9-month mark for a 12-month PA, or the 4-month mark for a 6-month PA, give the office enough lead time to submit reauthorization documentation before the original approval expires.

Key takeaways

• Pull the specific PA criteria from your insurer's provider or member portal before submission — successful PAs mirror the criteria document line by line.
• Document BMI with the value to one decimal place, the measurement date, and the height/weight used; for BMI near 27.0, a recent in-office weighing matters.
• Comorbidities supported by objective data (labs, imaging, sleep studies) are reviewed more favourably than comorbidities supported only by patient report.
• Address step therapy proactively: document prior weight-loss attempts with specifics, and document prior pharmacotherapy trials with dose, duration, and reason for discontinuation.
• Match the drug to the indication: Wegovy and Zepbound for obesity, Ozempic and Mounjaro for diabetes; off-label submissions for weight loss are usually denied.
• If denied, read the letter carefully — most denials are documentation-based and resolved on resubmission; peer-to-peer review and external appeal are escalation paths for substantive disputes.